Filing Details
- Accession Number:
- 0001493152-20-024310
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-28 09:53:02
- Reporting Period:
- 2020-12-22
- Accepted Time:
- 2020-12-28 09:53:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1394319 | Tracon Pharmaceuticals Inc. | "TCON" | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1595855 | Opaleye Management Inc. | One Boston Place, 26Th Floor Boston MA 02108 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2020-12-22 | 496,277 | $8.06 | 2,293,371 | No | 4 | P | Indirect | By Opaleye, L.P. |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By Opaleye, L.P. |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock, Par Value $0.001 Per Share | 225,000 | Indirect | By Managed Account |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Pre-funded warrant | $0.01 | 2020-08-27 | 2027-08-27 | 1,889,513 | 0 | Indirect |
Common Stock | Pre-funded warrant | $0.01 | 2020-08-31 | 2027-08-31 | 1,358,993 | 0 | Indirect |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2027-08-27 | 1,889,513 | 0 | Indirect |
2027-08-31 | 1,358,993 | 0 | Indirect |
Footnotes
- Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly bythe Fund.
- Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directlyby the Managed Account.
- The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 9.99% of the Issuer's then outstanding common stock.